Background: Normal pressure hydrocephalus (NPH) is considered potentially treatable with the placement of a cerebrospinal fluid (CSF) shunt. Yet, the procedure has had variable success, particularly with respect to improving the cognitive impairment in NPH. The presence of neurologic co-morbidities, particularly Alzheimer's Disease (AD), may contribute to shunt responsiveness. Uncovering the extent to which AD and NPH co-occur has implications for diagnosis and treatment of NPH. Autopsy studies of patients with NPH during life would elucidate the frequency of such co-morbidities.
Table of Contents
Introduction 5
Methods 7
Results 10
Discussion 12
Conclusions and Future Directions 15
References 16
Poster 22 Tables   Table 1: Clinical and neuropathological data for NPH cases 21
List of

Introduction
Normal pressure hydrocephalus (NPH), first described by Hakim and Adams (1), is characterized by the clinical triad of gait disturbance, cognitive impairment, and urinary incontinence along with radiological evidence of ventriculomegaly out of proportion to cortical atrophy. In practice, clinical presentation is variable, and diagnosis is based on a composite of clinical history, brain imaging, physical findings and physiological measures. ( 2) The only available treatment for NPH is the placement of a CSF shunt; however, identifying patients most likely to benefit has remained a challenge despite several shunt trials.
The recent advent of programmable shunts has brought new attention to NPH, prompting an increased vigilance for NPH and an increasing number of shunting procedures to treat NPH.
It has been theorized that the presence of neurologic co-morbidities in patients with clinical NPH may contribute to shunt responsiveness or lack thereof. Several studies have demonstrated neuropathologic evidence of Alzheimer's disease (AD) in NPH through cortical biopsies taken during shunt placement. The frequency of AD in cortical biopsy has been shown to be greater than that of the general population, suggesting an AD-NPH syndrome. This pathophysiologic relationship
has not yet been fully elucidated. One hypothesis is that altered CSF dynamics play a role in the pathologic build-up of beta-amyloid in the brain. (3, 4) Uncovering the extent to which AD and NPH co-occur has implications for diagnosis and treatment of NPH.
If an AD-NPH syndrome exists and is at least partly due to altered CSF dynamics, the restoration of proper CSF circulation would seem a reasonable therapeutic approach. Yet, studies have shown that the majority of persons with NPH and concomitant AD do not exhibit cognitive improvement after shunt placement. For these reasons, patient selection for shunt surgery has remained a challenge.
In order to gain insight into the neuropathology of NPH, we identified all NPH cases from our database of deceased donors and reviewed the medical records and autopsy findings of each case. Our analysis of clinical characteristics and neuropathologic diagnoses sheds light on the role of co-morbidities, particularly AD, in NPH. For this cliniconeuropathologic study, the BDP database was queried to identify all participants with neuropathological evidence of dementing illnesses. Frequencies of underlying cause were compared.
Methods
Subjects
Alzheimer's disease was diagnosed using NINCDS-ADRDA criteria, (6) vascular dementia (VaD) using NINDS-AIREN criteria, (7) dementia with Lewy bodies (DLB) according to the Consortium on Dementia with Lewy bodies criteria(8) and frontotemporal dementia (FTD) using the Lund and Manchester Groups criteria. (9) The database was also queried for all participants with a clinical diagnosis of normal pressure hydrocephalus during life. For our study, those fulfilling a diagnosis of NPH were noted to have gait disturbance and dementia with or without urinary incontinence. Imaging confirmation of dilated ventricles consistent with NPH was present in all cases. These criteria correspond to probable NPH as described by current evidence-based guidelines. (2) Of the identified NPH cases, we reviewed medical records from SHRI assessments as well as those received from outside physicians.
Abstracted information included clinical diagnoses, education, CSF shunt status, age at death, and neuropathologic diagnoses. were found to AD and 1/9 (11%) had progressive supranuclear palsy.
Concomitant neuropathologic diagnoses included: 1/9 DLB; 3/9 cerebral white matter rarefaction; 2/9 argyrophilic grains, mesial lobe.
Discussion
In this clinico-neuropathologic study of a cohort of brain donors with clinically-confirmed NPH during life, our most striking finding at autopsy is that 8 of 9 (89%) cases met NIA-Reagan criteria of AD. (12) We also found that NPH occurred in 1.6% (9/563) of all subjects with dementia in our database of deceased donors, corresponding to previous epidemiologic reports of NPH in 0-3% of dementia cases. (13, 14) In our series, NPH rarely exists in the absence of other neurodegenerative conditions and does not commonly appear to be a sole contributor to a dementia process.
There has been ongoing debate as to the validity of NPH as a true subjects with probable AD which found no benefit to low-flow CSF shunting in AD subjects. (22) Our study has several strengths. Comprehensive neuropathologic examinations were important to confirm post-mortem diagnoses.
Additionally, we were able to identify cases from a large database of clinical and neuropathologic data on deceased persons. This study is also strengthened by the review of detailed medical records from SHRI and from external clinicians.
The small sample size of NPH patients may limit the generalizability of the findings. However, the frequency of NPH in our sample was comparable to epidemiologic reports of NPH in dementia patients. 
Conclusions and Future Directions
It has been proposed that altered CSF dynamics exist in both AD and 
